AstraZeneca to receive up to $400 million to co-develop Parkinson’s drug

News

Author: Parkinson's Life editorsPublished: 31 August 2017

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

AstraZeneca and Takeda lead

AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after agreeing a deal to co-develop an early-stage medicine for Parkinson’s disease.

The drug, MEDI1341, is an antibody treatment and is due to enter phase I clinical trials later this year.

Mene Pangalos, executive vice president of AstraZeneca, said: “By combining our scientific expertise and sharing the risks and cost of development, we hope to accelerate the advancement of MEDI1341 as a promising new approach to support the treatment of people with Parkinson’s disease around the world.”

The two companies will share future development and commercialisation costs for MEDI1341 equally, in addition to future revenues.

Go Back

Share this story

Comments


Related articles


Close up of young woman talking to a doctor online

PD in Practice

Coronavirus and treatment for Parkinson’s

Four professionals share their thoughts on healthcare during the pandemic

READ MORE

Women and Parkinson's

“Finding information about being a woman with Parkinson’s was challenging”

Kathleen Reardon on diagnosis and being heard by doctors

READ MORE
greg-grindley-lead

Interviews

Dancing with my wife again: Greg Grindley on life one year after Brain Surgery Live

Find out how the man who had DBS live on TV is doing one year on

READ MORE